Dashboard PDUFA PDUFA History Dilution Watch Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Track AGMB with free AI briefings, catalyst countdowns, and dilution alerts.

AGMB · AgomAb Therapeutics NV

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$252M Cash on Hand

53.3mo Cash Runway

2.1% Short Interest

$37.67 Analyst Target (6)

Follow AGMB by email Get an email when AGMB pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about AGMB, unsubscribe in one click. Privacy

📣 What AGMB Says Is Next

coming months · Ontunisertib: “Next steps with ontunisertib: NOV-ERA Phase 2b study Agomab recently completed regulatory filings for NOV-ERA, a global Phase 2b trial designed to evaluate ontunisertib in approximately 320 patients with symptomatic FSCD and plans to initiate the study in the coming months.”
Company press release, Oct 1, 2026 · SEC filing
coming months · “We expect to report topline results from the IPF patient cohort in the coming months. o We are on track to initiate a Phase 2 trial with AGMB-447 in IPF in the second half of the year. o We were granted a patent covering the composition of matter of AGMB-447 by the United States Patent and Trademark Office (USPTO), solidifying the foundational intellectual property for AGMB-447 in the U.S. Half Year 2026 Financial Results (consolidated)”
Company press release, Aug 6, 2026 · SEC filing
second half of 2026 · “We plan to initiate the NOV-ERA study following receipt of applicable regulatory and ethics approvals and expect to dose the first participants in the second half of 2026. o We are progressing the OLE part of the STENOVA study (Part B) with ontunisertib in FSCD patients, with topline results expected in the coming months.”
Company press release, Aug 6, 2026 · SEC filing

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

🧪 Trial & FDA Catalysts

Dec 2028 · Phase 2 · Recruiting · NOV-ERA - A Clinical Trial to Assess the Efficacy and Safety of Ontunisertib Compared to P
Registry primary completion date, not a results date

📊 Drug Pipeline

Drug	Indication	Most advanced trial	Status
AGMB-129	Fibrostenotic Crohn's Disease	Phase 2 · NCT05843578	Completed
Ontunisertib	Fibrostenotic Crohn's Disease	Phase 2 · NCT07683325	Recruiting
[14C]ontunisertib	Fibrostenotic Crohn's Disease	Phase 1 · NCT07672574	Recruiting
AGMB-447	IPF	Phase 1 · NCT06181370	Completed
MDZ	Healthy Volunteers	Phase 1 · NCT05937386	Completed

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

AGMB holds $252M in cash and short-term investments and burns about $14.2M/quarter from operations, an estimated runway of 53.3 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 0 · Low

Cash runway 53 months
S-1 registration (Jan 2026) +8
Company says cash lasts into the first half of 2029 -15We expect our existing cash, cash equivalents and cash investments, including the net proceeds from our IPO, will be sufficient to fund our current operations into the first half of 2029. 20-F, Apr 2026
Raised after last reported balance sheet (Feb 2026) -10

Recent financing filings on SEC EDGAR:

Feb 6, 2026 · Underwritten offering · 424B4
Jan 16, 2026 · S-1 registration · F-1

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when AGMB files for a raise →

👥 Who Owns AGMB

Insiders 0.1% Other 5%+ holders 24.7% Institutions 75.2% Public and other holders 0%

Holder	Type	Shares	% of shares	As of
LSP 7 Cooperatieve U.A.	5%+ holder (13D)	5,141,992	15.05%	2026-02-09
Eqt Fund Management S.a R.l.	Institution (13F)	5,141,992	15.05%	2026-06-30
FMR LLC	Institution (13G, 5%+)	4,873,680	14.26%	2026-02-27
Pontifax VI G.P. L.P.	5%+ holder (13G)	3,305,846	9.68%	2026-03-31
SANOFI	Institution (13G, 5%+)	2,783,096	8.15%	2026-03-31
Redmile Group, LLC	Institution (13G, 5%+)	2,735,926	8.01%	2026-03-31
Cormorant Asset Management, LP	Institution (13G, 5%+)	2,465,348	7.22%	2026-03-31
TCG Crossover Management, LLC	Institution (13F)	2,053,233	6.01%	2026-06-30
Federated Hermes, Inc.	Institution (13F)	1,618,000	4.74%	2026-06-30
Nantahala Capital Management, LLC	Institution (13F)	1,568,188	4.59%	2026-06-30
Casdin Capital, LLC	Institution (13F)	1,550,000	4.54%	2026-06-30
Andera Partners	Institution (13F)	1,538,702	4.50%	2026-06-30

Share count 34,167,168 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the largest 13F holders (13F quarter ending 2026-06-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📈 Recent Insider Activity (Form 4)

Trade date	Insider	Transaction	Shares	Price	Owned after
2026-09-11 filed 2026-09-15	Patel Naimish	Option award (A)	56,328	–	–
2026-09-11 filed 2026-09-15	Garcia Marino	Option award (A)	57,482	–	–

Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.

Get the full AGMB picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for AGMB and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z